MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte ...
--New assays for the Panther Fusion and Novodiag Systems further build on Hologic’s leading molecular scalable solutions offering to European customers-- The Panther Fusion SARS-CoV-2/Flu A/B/RSV ...
Hologic, Inc. HOLX recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of ...
Hologic’s HOLX fully automated, high-throughput Panther platform remains the foundation of its molecular diagnostics business. The Panther Fusion module, a 2016 addition to the base system, provides ...
Hologic, Inc. HOLX recently expanded its Global Access Initiative (“GAI”) with the addition of the Aptima SARS-CoV-2 assay. The GAI’s all-inclusive pricing structure is anticipated to make the Aptima ...
Hologic HOLX has highlighted the role of its Panther Fusion platform in supporting the future growth of its Diagnostics business. Fusion is an add-on module to the base Panther system, providing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results